


REMARKS

The above amendments have been made to remove multiple dependencies from the claims and to conform them to U.S. practice. No new matter has been added.

Respectfully submitted,

NATH & ASSOCIATES PLLC

By: _____


Gary M. Nath

Registration Number 26,965

Tanya E. Harkins

Registration Number 52,993

Customer Number 20529

Date: December 17, 2004

NATH & ASSOCIATES PLLC

1030th Street, NW - 6th Floor

Washington, D.C. 20005-1503

GMN/TEH/le

Claims

1. (original) A method for the diagnosis and/or therapy of NIS gene-expressing carcinomas and/or metastases, in which uptake of substances which are actively transported by the NIS symporter into the cells of carcinomas and/or metastases is stimulated and/or enhanced by means of induction of NIS gene expression in these cells.

2. (original) The method as claimed in claim 1, characterized in that the NIS gene-expressing carcinomas and/or metastases are primary tumors and/or metastases of glandular carcinomas, in particular salivary gland carcinomas, thyroid carcinomas, uterine carcinomas and/or carcinomas of the breast.

3. (currently amended) The method as claimed in claim 1 ~~or claim 2~~, characterized in that the induction of NIS gene expression takes place by treatment with active compounds, in particular with at least one PPAR- γ ligand and at least one RAR and/or RXR ligand.

4. (original) The method as claimed in claim 3, characterized in that the at least one PPAR- γ ligand is a thiazolidinedione, in particular from the group consisting of ciglitazone, pioglitazone, rosiglitazone or mixtures thereof.

5. (currently amended) The method as claimed in claim 3 ~~or claim 4~~, characterized in that the at least one RAR and/or RXR

Preliminary Amendment with Attachment A

National Phase of PCT/EP03/06435

Attorney Docket: 26465U

Page 2

ligand is retinoic acid, in particular *trans*-retinoic acid, and/or at least one pharmacologically acceptable derivative thereof.

6. (original) The method as claimed in claim 5, characterized in that the pharmacologically acceptable derivative is a salt or an ester, in particular an ester with an alkanolic acid preferably having 1 to 4 C atoms.

7. (currently amended) The method as claimed in ~~any of claims 3 to 6~~, claim 3, characterized in that at least one substance which modulates, in particular enhances, the stimulation and/or the enhancement by the active compounds is additionally administered, where the substance preferably antagonizes at least one suppressor of NIS gene expression, in particular a liver lipid receptor and/or a thyroid hormone receptor.

8. (currently amended) The method as claimed in ~~any of claims 1 to 7~~, claim 1, characterized in that the substance which is actively transported by the NIS symporter into the cells of carcinomas and/or metastases is a halogen, in particular iodine, where the iodine is preferably in the form of an alkali metal and/or alkaline earth metal iodide, preferably of sodium iodide.

9. (currently amended) The method as claimed in ~~any of claims 1 to 8~~, claim 1, characterized in that the substance which is actively transported by the NIS symporter into the cells of carcinomas and/or metastases is technetium.

Preliminary Amendment with Attachment A

National Phase of PCT/EP03/06435

Attorney Docket: 26465U

Page 3

10. (currently amended) The method as claimed in ~~any of claims 1 to 9~~, claim 1, characterized in that the substance which is actively transported by the NIS symporter into the cells of carcinomas and/or metastases is radioactive, in particular radioactive iodine, preferably ^{123}I , ^{125}I and/or ^{131}I .

11. (currently amended) The method as claimed in ~~any of claims 3 to 10~~, claim 3, characterized in that the at least one RAR/RXR ligand is administered first and the at least one PPAR- γ ligand is administered after an appropriate time, in particular after about some hours to about some days, preferably after about 1 to about 3 days.

12. (currently amended) The method as claimed in ~~any of claims 1 to 11~~, claim 1, characterized in that metastases with a diameter of less than about 1 cm, in particular less than about 0.5 cm, can be diagnosed and/or treated.

13. (original) A method for the *in vivo* diagnosis of NIS gene-expressing carcinomas and/or metastases of carcinomas, in particular of glandular carcinomas, preferably salivary gland carcinomas, thyroid carcinomas, uterine carcinomas and/or carcinomas of the breast, which includes at least the following steps:

- a) administration of active compounds which are able to stimulate and/or to enhance induction of NIS gene expression in cells of carcinomas and/or

Preliminary Amendment with Attachment A

National Phase of PCT/EP03/06435

Attorney Docket: 26465U

Page 4

metastases,

b) administration of at least one substance which can be actively transported by the NIS symporter into the cells, in particular of radioactive iodine and/or technetium,

c) determination of the uptake of said substance by the cells, in particular by means of a local scintigram and/or of a whole-body scintigram.

14. (original) A method for the *in vitro* diagnosis of NIS gene-expressing carcinomas and/or metastases of carcinomas, in particular of glandular carcinomas, preferably salivary gland carcinomas, thyroid carcinomas, uterine carcinomas and/or carcinomas of the breast, which includes at least the following steps:

a) incubation of cells of a sample to be investigated with active compounds which are able to stimulate and/or to enhance induction of NIS gene expression in cells of carcinomas and/or metastases,

b) incubation of the cells obtained in the first step with at least one substance which can be actively transported by the NIS symporter into the cells, in particular with radioactive iodine and/or technetium,

c) determination of the uptake of said substance by the cells.

15. (original) A method for the *in vitro* diagnosis of NIS gene-

Preliminary Amendment with Attachment A

National Phase of PCT/EP03/06435

Attorney Docket: 26465U

Page 5

expressing carcinomas and/or metastases of carcinomas, in particular of glandular carcinomas, preferably salivary gland carcinomas, thyroid carcinomas, uterine carcinomas and/or carcinomas of the breast, which includes at least the following steps:

- a) incubation of cells of a sample to be investigated with active compounds which are able to stimulate and/or to enhance induction of NIS gene expression in cells of carcinomas and/or metastases,
- b) determination of the expression of NIS mRNA by the cells, in particular by means of reverse transcriptase polymerase chain reaction (RT-PCR).

16. (original) A composition for a diagnosis and/or therapy of NIS gene-expressing carcinomas and/or metastases, characterized in that this composition comprises active compounds which stimulate and/or enhance induction of NIS gene expression in the cells of carcinomas and/or metastases.

17. (original) The composition as claimed in claim 16, characterized in that the NIS gene-expressing carcinomas and/or metastases are primary tumors and/or metastases of glandular carcinomas, in particular salivary gland carcinomas, thyroid carcinomas, uterine carcinomas and/or carcinomas of the breast.

18. (currently amended) The composition as claimed in claim 16 ~~or claim 17~~, characterized in that the active compounds are at least one PPAR- γ ligand and at least one RAR and/or RXR ligand.

Preliminary Amendment with Attachment A

National Phase of PCT/EP03/06435

Attorney Docket: 26465U

Page 6

19. (original) The composition as claimed in claim 18, characterized in that the PPAR- γ ligand is a thiazolidinedione, in particular from the group consisting of ciglitazone, pioglitazone, rosiglitazone or mixtures thereof.

20. (currently amended) The composition as claimed in claim 18 ~~or claim 19~~, characterized in that the RAR and/or RXR ligand is retinoic acid, in particular trans-retinoic acid, and/or at least one pharmacologically acceptable derivative thereof.

21. (original) The composition as claimed in claim 20, characterized in that the pharmacologically acceptable derivative is a salt or an ester, in particular an ester with an alkanolic acid preferably having 1 to 4 C atoms.

22. (currently amended) The composition as claimed in ~~any of claims 16 to 21~~, claim 16, characterized in that it additionally comprises at least one substance which modulates, in particular enhances, the stimulation and/or enhancement by the active compounds, where the substance preferably antagonizes at least one suppressor of NIS gene expression, in particular a liver lipid receptor and/or a thyroid hormone receptor.

23. (currently amended) The composition as claimed in ~~any of claims 16 to 22~~, claim 16, characterized in that it additionally comprises a histone deacetylase inhibitor, in particular trichostatin A and/or a butyrate.

Preliminary Amendment with Attachment A

National Phase of PCT/EP03/06435

Attorney Docket: 26465U

Page 7

24. (currently amended) The composition as claimed in ~~any of claims 16 to 23,~~ claim 16, characterized in that it additionally includes at least one pharmacologically acceptable carrier and/or excipient.

25. (currently amended) The composition as claimed in ~~any of claims 16 to 24,~~ claim 16, characterized in that it is intended for oral and/or parenteral administration.

26. (currently amended) A combination product in the form of a kit including spatially separated from one another the composition as claimed in ~~any of claims 16 to 25,~~ claim 16, and at least one substance which can be actively transported by the NIS symporter into the cells of carcinomas and/or metastases, for separate, where appropriate sequential, use for diagnosis and/or therapy of NIS gene-expressing carcinomas and/or metastases, in particular of glandular carcinomas, preferably salivary gland carcinomas, thyroid carcinomas, uterine carcinomas and/or carcinomas of the breast.

27. (original) The combination product as claimed in claim 26, characterized in that the substance which is actively transported by the NIS symporter into the cells of carcinomas and/or metastases is a halide, in particular iodine, and/or technetium.

28. (currently amended) The combination product as claimed in

Preliminary Amendment with Attachment A

National Phase of PCT/EP03/06435

Attorney Docket: 26465U

Page 8

claim 26 ~~or claim 27~~, characterized in that the substance which is actively transported by the NIS symporter into the cells of carcinomas and/or metastases is radioactive.

29. (original) The combination product as claimed in claim 28, characterized in that the radioactive substance is radioactive iodine ^{123}I , ^{125}I and/or ^{131}I , which is in particular in the form of an alkali metal or alkaline earth metal iodide, preferably of sodium iodide.

30. (original) The use of at least one PPAR- γ ligand and at least one RAR and/or RXR ligand for producing a diagnostic composition for detecting carcinomas and/or metastases which express at least one NIS gene.

31. (original) The use of at least one PPAR- γ ligand and at least one RAR and/or RXR ligand for producing a medicament for treating carcinomas and/or metastases which express at least one NIS gene.

32. (currently amended) The use as claimed in claim 30 ~~or claim 31~~, characterized in that the carcinomas and/or metastases are primary tumors and/or metastases of glandular carcinomas, in particular salivary gland carcinomas, thyroid carcinomas, uterine carcinomas and/or carcinomas of the breast.

33. (currently amended) The use as claimed in ~~any of claims 30 to 32~~, claim 30, characterized in that the at least one PPAR- γ

Preliminary Amendment with Attachment A

National Phase of PCT/EP03/06435

Attorney Docket: 26465U

Page 9

ligand is a thiazolidinedione, in particular from the group consisting of ciglitazone, pioglitazone, rosiglitazone or mixtures thereof.

34. (currently amended) The use as claimed in ~~any of claims 30 to 33,~~ claim 30, characterized in that the at least one RAR and/or RXR ligand is retinoic acid, in particular *trans*-retinoic acid, and/or at least one pharmacologically acceptable derivative thereof.

35. (original) The use as claimed in claim 34, characterized in that the pharmacologically acceptable derivative is a salt or an ester, in particular an ester with an alkanolic acid preferably having 1 to 4 C atoms.

36. (currently amended) The use as claimed in ~~any of claims 30 to 35,~~ claim 30, characterized in that the diagnostic composition and/or the medicament additionally includes at least one substance which modulates, in particular enhances, a stimulation and/or enhancement of NIS gene expression by the active compounds, where the substance preferably antagonizes at least one suppressor of NIS gene expression, in particular a liver lipid receptor and/or a thyroid hormone receptor.

37. (currently amended) The use as claimed in ~~any of claims 30 to 36,~~ claim 30, characterized in that the diagnostic composition and/or the medicament is intended to be employed for combination with a substance which is actively transported by

Preliminary Amendment with Attachment A

National Phase of PCT/EP03/06435

Attorney Docket: 26465U

Page 10

the NIS symporter, in particular a halide, preferably iodine, and/or technetium, where the iodine is preferably in the form of an alkali metal and/or alkaline earth metal iodide, preferably of sodium iodide.

38. (original) The use as claimed in claim 37, characterized in that the substance is a radioactive substance, in particular radioactive iodine, preferably ^{123}I , ^{125}I and/or ^{131}I .

39. (currently amended) The use as claimed in ~~any of claims 30 to 38,~~ claim 30, characterized in that the diagnostic composition and/or the medicament is intended to be administered so that the at least one RAR and/or RXR ligand is administered first and the at least one PPAR ligand is administered after an appropriate time, in particular after about some hours to about some days, preferably after about 1 to about 3 days.